A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Trial Profile

A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 15 Nov 2017 According to a Noden Pharma media release, the US Food and Drug Administration has approved Aliskiren oral pellets for the treatment of hypertension in adults and children six years of age and older. The new pellet formulation and pediatric indication were approved through the FDA priority review process.
    • 27 Aug 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
    • 15 Apr 2014 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top